STLN: Financial results

Item 2.02. Results of Operations and Financial Condition On November 5, 2026, Starling Oncology, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2026 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in Item 2.02 of this Current Report and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release issued by Starling Oncology, Inc. on November 5, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 5, 2026 STARLING ONCOLOGY, INC. By: /s/ Robert Carter Name: Robert Carter Title: Chief Financial Officer